This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Ajinomoto Co., Ltd., Ea Pharma Co., Ltd.. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Tomohiro Fujii: Innovator in Protein Modification and Medicinal Chemistry
Introduction
Tomohiro Fujii is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the fields of protein modification and medicinal chemistry. With a total of 2 patents, his work focuses on innovative compounds that enhance the functionality of soluble proteins and provide therapeutic benefits.
Latest Patents
Fujii's latest patents include a compound that has an affinity substance to soluble protein, a cleavable portion, and a reactive group. This invention enables the regioselective modification of soluble proteins, which is crucial for various biochemical applications. Another significant patent involves a heterocyclic sulfonamide derivative that exhibits superior TRPA1 antagonist activity. This compound can be utilized in the development of medications for the prophylaxis or treatment of diseases related to TRPA1.
Career Highlights
Throughout his career, Tomohiro Fujii has worked with prominent companies such as Ajinomoto Co., Ltd. and Ea Pharma Co., Ltd. His experience in these organizations has allowed him to refine his expertise in the development of innovative pharmaceutical compounds.
Collaborations
Fujii has collaborated with notable coworkers, including Kei Yamada and Tatsuya Okuzumi. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Tomohiro Fujii's contributions to the fields of protein modification and medicinal chemistry highlight his innovative spirit and dedication to advancing scientific knowledge. His patents reflect a commitment to developing solutions that can have a meaningful impact on health and medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

